Overall, our hope is that the fxn deficiency model described here will prove useful to other FRDA researchers in the collective effort to understand the effects of decreased FXN expression in humans, and to assist with efforts to identify new therapeutics to treat this devastating condition. The gene discussed is FXN; the disease is Friedreich ataxia.